Azithromycin for oral suspension USP

• Each 5ml reconstituted suspension contains
• Azithromycin(as dihydrate) USP Eq. to Azithromycin (Anhydrous) 200 mg
• Excipients  q.s.
• For thetreatment of patients with mild to moderate infections caused by susceptiblestrains of the designated microorganisms in the specific conditions listedbelow:

• Acute Bacterial Exacerbations of Chronic Obstructive Pulmonary Disease and Acute bacterial sinusitis:   Due  to   Haemophilus   influenzae,  Moraxella   catarrhalis,   or Streptococcus pneumonia.
• Community-Acquired  Pneumonia: Due  to  Chlamydia pneumoniae,  Haemophilus influenzae, Mycoplasma  pneumoniae,  or Streptococcus  pneumoniae  in patients appropriate for oral therapy.
• Pharyngitis/Tonsillitis: Caused byStreptococcus pyogenesasan alternative to first-line therapy in individuals whocannot use first-line therapy.
• Uncomplicated Skin and Skin StructureInfections: Due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae.
• Urethritis and Cervicitis: Due to Chlamydiatrachomatis or Neisseria gonorrhoeae.
• Genital Ulcer Disease:In men due to Haemophilusducreyi (chancroid). Due to the small number of women included in clinicaltrials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 

• Acute  otitis   media:   due   to  Haemophilus   influenzae,   Moraxella  catarrhalis   or Streptococcuspneumoniae.
• Community  acquired   pneumonia:   due  to   Chlamydia   pneumoniae,  Haemophilus influenzae, Mycoplasma  pneumoniae   or   Streptococcus   pneumoniae  in   patients appropriate for oral therapy.
• Pharyngitis/Tonsillitis:  due to Streptococcus  pyogenes as  an  alternative to  first-line therapy in individuals who cannot use first-line therapy.

 Product details